Date: 2015-04-29
Type of information: Collaboration agreement
Compound: small molecules having a positive effect on SMCHD1 and DUX4 activity
Company: Evotec (Germany) Facio Therapies (The Netherlands)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: collaboration
Action mechanism:
Disease: facioscapulohumeral dystrophy
Details: * On April 29, 2015, Evotec and Facio Therapies announced that they have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD (Facioscapulohumeral dystrophy), a muscle wasting disease. This agreement marks the start of finding a drug to overcome FSHD. The project with Facio entails the set-up and execution of an automated high-throughput screen to identify small molecules having a positive effect on SMCHD1 and DUX4 activity in human FSHD-affected muscle cell lines. The compounds that show promising activity in this screen are expected to be available in the first half of 2016. These compounds will require extensive further testing to produce compounds that are suitable for the development of a therapeutic for the treatment of FSHD. All in all, this is a challenging process that may take several years before clinical testing in humans can begin.
Financial terms: No financial details were disclosed.
Latest news:
